Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib DDI with Atorvastatin and Rosuvastatin
NCT06081166Phase 1Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of obicetrapib in hypercholesterolemia and dyslipidemia (2 arms), sponsored by NewAmsterdam Pharma. Primary endpoints: Plasma concentrations of Atorvastatin and Plasma concentrations of Rosuvastatin. Started Nov 2023; status: completed.
02
Drugs
obicetrapib
03
Conditions
hypercholesterolemiadyslipidemia
Beyond the preview
Go deeper on NCT06081166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081166.